Omalizumab: a novel steroid sparing agent in eosinophilic granulomatosis with polyangiitis?
M
M
Latorre
C
C
Baldini
V
V
Seccia
C
C
Notarstefano
A
A
Della Rossa
C
C
Tani
R
R
Talarico
M
M
Mosca
P L
PL
Paggiaro
D000328:Adult; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D015267:Churg-Strauss Syndrome / Q000188:drug therapy*; D057915:Drug Substitution; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D000069444:Omalizumab; D012074:Remission Induction; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D013256:Steroids; D000069444:Omalizumab